Study to compare the effect of ipilimumab retreatment with chemotherapy in advanced melanoma

Registry ID

EUCTR2012-003291-38

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Bristol-Myers Squibb International Corporation

Start date

2013-01-29

Completion date

2014-07-04

Last update

2026-08-16

Conditions

• Advanced Melanoma

Summary

The purpose of the study is to compare the 18-month overall survival rate in subjects with advanced melanoma receiving ipilimumab monotherapy (3 mg/kg) as retreatment versus chemotherapy of investigator’s choice in subjects who are randomized at the time of ipilimumab retreatment eligibility. This comparison will be done after the last randomized subject had the chance to be followed for 18 months.

Locations

• , , Belgium
• , , Germany
• , , UK
• , , Austria
• , , Italy

Related clinical trials

• A Clinical Study of T3011 in Subjects With Advanced Melanoma
• Sitagliptin With Pembro in RCC and Melanoma
• Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors
• VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
• High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial
• AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

View on source registry